Uncategorized
Ranibizumab improves BCVA in patients with myopic choroidal neovascularization
ORLANDO, Fla. — Best corrected visual acuity improved in patients with myopic choroidal neovascularization treated with ranibizumab, according to the RADIANCE study presented here at the Association for Research in Vision and Ophthalmology meeting.“Regardless of baseline ocular characteristics, ranibizumab treatment guided by disease activity criteria led to similar and effective BCVA improvements across all the subgroups analyzed,” Nicolas Leveziel, MD, PhD, and colleagues said in the poster.